ALIS added to therapy improved outcomes in new MAC lung disease

The ENCORE phase 3b randomized, double-blind trial compared amikacin liposome inhalation suspension (ALIS) plus multidrug therapy against placebo plus multidrug therapy in 425 adults newly diagnosed with Mycobacterium avium complex lung disease who had not yet started antibiotics. The trial reported significantly greater improvement in respiratory symptom scores and significantly higher rates of culture conversion and durable culture conversion in the ALIS arm compared with the comparator arm, with no new safety signals observed.

Most relevant for: Adults newly diagnosed with Mycobacterium avium complex lung disease who have not yet initiated antibiotic therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.